ReviewCurrent pharmaceutical design2026
Targeting Ocular Tissue through Surface-Modified and Multifunctional Biomaterials and mRNA-Based Therapeutics.
Review in Current pharmaceutical design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeting the ocular surfaces and improving retention time are crucial to achieving high therapeutic outcomes for eye diseases. The most frequently used ophthalmic preparation is ocular drops, which, however, come with various limitations; therefore, advanced eye formulations are essential for the ocular medical field. Different methods, such as penetration enhancers, nanoparticles, ocular inserts, and lenses, have been utilized to improve the eye retention time. Although these formulations present limited advantages, combining them with surface-modified polymers can improve the therapeutic outcomes. Surface modification can be achieved through physical, chemical, and other methods. Chemical grafting is one of the most preferable methods, given that it is a straightforward methodology. This review summarizes the ocular microenvironment and eye barriers that should be overcome when designing ocular drug delivery systems. Most importantly, it summarizes ocular drug delivery systems based on surface-modified materials and emerging nanocarriers, also combined with IVT-mRNA therapeutics, offering promising advancements by enhancing targeting precision and therapeutic efficacy.
Indexed as
Identifiers
40621762What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.